Developing a new cell therapy to combat drug resistance in lung cancer
Personalization and Failure Testing of Dual Switch Gene Drives in Lung Cancer
This study is testing a new type of cell therapy for people with non-small-cell lung cancer that helps the treatment adapt to the tumor's changes, aiming to make it more effective for those who struggle with drug resistance.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Pennsylvania State University, the NIH-funded |
| Lab location | 1 site (University Park, United States) |
| Project ID | NIH-10977533 on NIH RePORTER |
What this research studies
This research focuses on creating a novel cell therapy designed to address the challenge of drug resistance in patients with non-small-cell lung cancer (NSCLC). By utilizing synthetic biology, the therapy aims to engineer tumor evolution in real-time, allowing the treatment to adapt to the changing environment of the tumor. The approach involves using dual-switch gene drives that can sense and respond to therapeutic conditions, potentially improving the effectiveness of existing treatments. Patients may benefit from a more personalized and effective treatment strategy that can overcome resistance mechanisms.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-small-cell lung cancer who have experienced or are at risk of developing drug resistance.
Not a fit: Patients with lung cancer types other than non-small-cell lung cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for lung cancer patients by overcoming drug resistance.
How similar studies have performed: While the approach of using synthetic biology in cancer treatment is innovative, similar strategies have shown promise in other areas of cancer research, indicating potential for success.
Where this research is happening
University Park, United States
- Pennsylvania State University, the — University Park, United States (Active)
Researchers
- Principal investigator: Pritchard, Justin — Pennsylvania State University, the
- Study coordinator: Pritchard, Justin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.